2-Pyrazinecarboxamide, 3,5-diamino-N-(aminoiminomethyl)-6-chloro-, hydrochloride, hydrate (1:1:2)
-
2-Pyrazinecarboxamide, 3,5-diamino-N-(aminoiminomethyl)-6-chloro-, hydrochloride, hydrate (1:1:2)
structure -
-
CAS No:
17440-83-4
-
Formula:
C6H8ClN7O.ClH.2H2O
-
Chemical Name:
2-Pyrazinecarboxamide, 3,5-diamino-N-(aminoiminomethyl)-6-chloro-, hydrochloride, hydrate (1:1:2)
-
Synonyms:
2-Pyrazinecarboxamide,3,5-diamino-N-(aminoiminomethyl)-6-chloro-,hydrochloride,hydrate (1:1:2);Pyrazinecarboxamide,N-amidino-3,5-diamino-6-chloro-,monohydrochloride,dihydrate;Pyrazinecarboxamide,3,5-diamino-N-(aminoiminomethyl)-6-chloro-,monohydrochloride,dihydrate;N-Amidino-3,5-diamino-6-chloropyrazinamide hydrochloride dihydrate;3,5-Diamino-N-carbamimidoyl-6-chloropyrazine-2-carboxamide dihydrate hydrochloride
- Categories:
-
CAS No:
Description
Pale yellow or greenish-yellow powder.ChEBI: A hydrate that is the dihydrate of amiloride hydrochloride.
Amiloride hydrochloride dihydrate is a hydrate that is the dihydrate of amiloride hydrochloride. It has a role as a diuretic and a sodium channel blocker. It contains an amiloride hydrochloride.|Amiloride Hydrochloride is the hydrochloride salt of amiloride, a synthetic pyrazine derivative with antikaliuretic and diuretic properties. Amiloride inhibits sodium channels located in the distal tubules and collecting ducts of the kidney, thereby preventing the absorption of sodium and increasing its excretion along with water, to produce naturesis. In response to the hypernatremic conditions in the kidney, the plasma membrane becomes hyperpolarized and electrochemical forces are reduced, which then prevents the excretion of potassium and hydrogen into the lumen.|A pyrazine compound inhibiting SODIUM reabsorption through SODIUM CHANNELS in renal EPITHELIAL CELLS. This inhibition creates a negative potential in the luminal membranes of principal cells, located in the distal convoluted tubule and collecting duct. Negative potential reduces secretion of potassium and hydrogen ions. Amiloride is used in conjunction with DIURETICS to spare POTASSIUM loss. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p705)
2-Pyrazinecarboxamide, 3,5-diamino-N-(aminoiminomethyl)-6-chloro-, hydrochloride, hydrate (1:1:2) Basic Attributes
302.12
301.045685
217-958-2
FZJ37245UC
DTXSID80169826
C47390
2933995300
Characteristics
161
1.94440
285-288 °C
628.1ºC at 760 mmHg
333.7ºC
Soluble in water at 50mg/ml
1.08E-15mmHg at 25°C
Safety Information
6.1
NONH for all modes of transport
3
UQ2275500
P264, P270, P273, P280, P301+P310, P305+P351+P338, P321, P330, P337+P313, P405, P501
H300
|Danger|H300 (90.24%): Fatal if swallowed [Danger Acute toxicity, oral]|P264, P270, P273, P280, P301+P310, P305+P351+P338, P321, P330, P337+P313, P405, and P501|Aggregated GHS information provided by 41 companies from 5 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
Drug Information
A subclass of sodium channel blockers that are specific for EPITHELIAL SODIUM CHANNELS. (See all compounds classified as Epithelial Sodium Channel Blockers.)|A subclass of sodium channel blockers that are specific for ACID-SENSING SODIUM CHANNELS. (See all compounds classified as Acid Sensing Ion Channel Blockers.)|Agents that promote the excretion of urine through their effects on kidney function. (See all compounds classified as Diuretics.)
Amidal
2-Pyrazinecarboxamide, 3,5-diamino-N-(aminoiminomethyl)-6-chloro-, hydrochloride, hydrate (1:1:2) Use and Manufacturing
An epithelial sodium channel blocker
Human drugs -> Rare disease (orphan)
Computed Properties
Molecular Weight:302.12
Hydrogen Bond Donor Count:7
Hydrogen Bond Acceptor Count:7
Rotatable Bond Count:1
Exact Mass:301.0456927
Monoisotopic Mass:301.0456927
Topological Polar Surface Area:161
Heavy Atom Count:18
Complexity:279
Covalently-Bonded Unit Count:4
Compound Is Canonicalized:Yes
Latest News on 2-Pyrazinecarboxamide, 3,5-diamino-N-(aminoiminomethyl)-6-chloro-, hydrochloride, hydrate (1:1:2)
- BMS Over $900 Million to Help Develop Potential 'Best-in-class' SHP2 Inhibitors
- AbbVie's blockbuster product for atopic dermatitis, Upadacitinib, has been approved for marketing in the EU and Japan
- Designing peptide inhibitors for possible COVID-19 treatments
- Chinese scientists discover the inhibitors of SARS-CoV-2
Learn More Other Chemicals
-
1-Pyrrolidineethanamine, β-[(2-methylpropoxy)methyl]-N-phenyl-N-(phenylmethyl)-, hydrochloride, hydrate (1:1:1)
74764-40-2
-
Hydrazine, (2,3-dimethylphenyl)-, hydrochloride, hydrate (1:1:?)
123333-92-6
-
4-Thiazolemethanamine, 2-(3-chlorophenyl)-, hydrochloride, hydrate (1:1:1)
690632-12-3
-
2-Piperidinecarboxamide, 1-butyl-N-(2,6-dimethylphenyl)-, hydrochloride, hydrate (1:1:1) Formula
73360-54-0
-
2-Piperidinecarboxamide, N-(2,6-dimethylphenyl)-1-propyl-, hydrochloride, hydrate (1:1:1), (2S)- Formula
132112-35-7
-
[1,1′-Biphenyl]-4,4′-diamine, 2,2′-dimethyl-, hydrochloride, hydrate (1:2:1) Formula
308103-59-5
-
Piperidine, 1-methyl-3-(9H-thioxanthen-9-ylmethyl)-, hydrochloride, hydrate (1:1:1) Structure
7081-40-5
-
Piperazine, hydrochloride, hydrate (1:2:1) Structure
6091-62-9
-
What is 3H-Pyrido[3,4-b]indole, 4,9-dihydro-7-methoxy-1-methyl-, hydrochloride, hydrate (1:1:2)
6027-98-1
-
What is Benzenecarboximidamide, hydrochloride, hydrate (1:1:?)
206752-36-5
2-Pyrazinecarboxamide, 3,5-diamino-N-(aminoiminomethyl)-6-chloro-, hydrochloride, hydrate (1:1:2)
SDSRequest for Quotation